Dustin W Wooten1,2, Nicolas J Guehl1,2, Eline E Verwer1,2, Timothy M Shoup1,2, Daniel L Yokell1,2, Nevena Zubcevik3, Neil Vasdev1,2, Ross D Zafonte3,4, Keith A Johnson2, Georges El Fakhri1,2, Marc D Normandin5,2. 1. Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 2. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 3. Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Massachusetts General Hospital, Boston, Massachusetts; and. 4. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts normandin@mgh.harvard.edu.
Abstract
18F-T807 is a PET radiotracer developed for imaging tau protein aggregates, which are implicated in neurologic disorders including Alzheimer disease and traumatic brain injury (TBI). The current study characterizes 18F-T807 pharmacokinetics in human subjects using dynamic PET imaging and metabolite-corrected arterial input functions. Methods: Nine subjects (4 controls, 3 with a history of TBI, 2 with mild cognitive impairment due to suspected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of 18F-T807 with arterial blood sampling. Total volume of distribution (VT) was estimated using compartmental modeling (1- and 2-tissue configurations) and graphical analysis techniques (Logan and multilinear analysis 1 [MA1] regression methods). Reference region-based methods of quantification were explored including Logan distribution volume ratio (DVR) and static SUV ratio (SUVR) using the cerebellum as a reference tissue. Results: The percentage of unmetabolized 18F-T807 in plasma followed a single exponential with a half-life of 17.0 ± 4.2 min. Metabolite-corrected plasma radioactivity concentration fit a biexponential (half-lives, 18.1 ± 5.8 and 2.4 ± 0.5 min). 18F-T807 in gray matter peaked quickly (SUV > 2 at ∼5 min). Compartmental modeling resulted in good fits, and the 2-tissue model with estimated blood volume correction (2Tv) performed best, particularly in regions with elevated binding. VT was greater in mild cognitive impairment subjects than controls in the occipital, parietal, and temporal cortices as well as the posterior cingulate gyrus, precuneus, and mesial temporal cortex. High focal uptake was found in the posterior corpus callosum of a TBI subject. Plots from Logan and MA1 graphical methods became linear by 30 min, yielding regional estimates of VT in excellent agreement with compartmental analysis and providing high-quality parametric maps when applied in voxelwise fashion. Reference region-based approaches including Logan DVR (t* = 55 min) and SUVR (80- to 100-min interval) were highly correlated with DVR estimated using 2Tv (R2 = 0.97, P < 0.0001). Conclusion: 18F-T807 showed rapid clearance from plasma and properties suitable for tau quantification with PET. Furthermore, simplified approaches using DVR (t* = 55 min) and static SUVR (80-100 min) with cerebellar reference tissue were found to correlate highly with compartmental modeling outcomes.
18F-T807 is a PET radiotracer developed for imaging tau protein aggregates, which are implicated in neurologic disorders including Alzheimer disease and traumatic brain injury (TBI). The current study characterizes 18F-T807 pharmacokinetics in human subjects using dynamic PET imaging and metabolite-corrected arterial input functions. Methods: Nine subjects (4 controls, 3 with a history of TBI, 2 with mild cognitive impairment due to suspected Alzheimer disease) underwent dynamic PET imaging for up to 120 min after bolus injection of 18F-T807 with arterial blood sampling. Total volume of distribution (VT) was estimated using compartmental modeling (1- and 2-tissue configurations) and graphical analysis techniques (Logan and multilinear analysis 1 [MA1] regression methods). Reference region-based methods of quantification were explored including Logan distribution volume ratio (DVR) and static SUV ratio (SUVR) using the cerebellum as a reference tissue. Results: The percentage of unmetabolized 18F-T807 in plasma followed a single exponential with a half-life of 17.0 ± 4.2 min. Metabolite-corrected plasma radioactivity concentration fit a biexponential (half-lives, 18.1 ± 5.8 and 2.4 ± 0.5 min). 18F-T807 in gray matter peaked quickly (SUV > 2 at ∼5 min). Compartmental modeling resulted in good fits, and the 2-tissue model with estimated blood volume correction (2Tv) performed best, particularly in regions with elevated binding. VT was greater in mild cognitive impairment subjects than controls in the occipital, parietal, and temporal cortices as well as the posterior cingulate gyrus, precuneus, and mesial temporal cortex. High focal uptake was found in the posterior corpus callosum of a TBI subject. Plots from Logan and MA1 graphical methods became linear by 30 min, yielding regional estimates of VT in excellent agreement with compartmental analysis and providing high-quality parametric maps when applied in voxelwise fashion. Reference region-based approaches including Logan DVR (t* = 55 min) and SUVR (80- to 100-min interval) were highly correlated with DVR estimated using 2Tv (R2 = 0.97, P < 0.0001). Conclusion:18F-T807 showed rapid clearance from plasma and properties suitable for tau quantification with PET. Furthermore, simplified approaches using DVR (t* = 55 min) and static SUVR (80-100 min) with cerebellar reference tissue were found to correlate highly with compartmental modeling outcomes.
Authors: E D Agdeppa; V Kepe; J Liu; S Flores-Torres; N Satyamurthy; A Petric; G M Cole; G W Small; S C Huang; J R Barrio Journal: J Neurosci Date: 2001-12-15 Impact factor: 6.167
Authors: Timothy M Shoup; Daniel L Yokell; Peter A Rice; Raul N Jackson; Eli Livni; Keith A Johnson; Thomas J Brady; Neil Vasdev Journal: J Labelled Comp Radiopharm Date: 2013-07-24 Impact factor: 1.921
Authors: Sergey Shcherbinin; Adam J Schwarz; Abhinay Joshi; Michael Navitsky; Matthew Flitter; William R Shankle; Michael D Devous; Mark A Mintun Journal: J Nucl Med Date: 2016-05-05 Impact factor: 10.057
Authors: J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley Journal: J Cereb Blood Flow Metab Date: 1990-09 Impact factor: 6.200
Authors: Ann C McKee; Robert A Stern; Christopher J Nowinski; Thor D Stein; Victor E Alvarez; Daniel H Daneshvar; Hyo-Soon Lee; Sydney M Wojtowicz; Garth Hall; Christine M Baugh; David O Riley; Caroline A Kubilus; Kerry A Cormier; Matthew A Jacobs; Brett R Martin; Carmela R Abraham; Tsuneya Ikezu; Robert Ross Reichard; Benjamin L Wolozin; Andrew E Budson; Lee E Goldstein; Neil W Kowall; Robert C Cantu Journal: Brain Date: 2012-12-02 Impact factor: 13.501
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: Mark Jenkinson; Christian F Beckmann; Timothy E J Behrens; Mark W Woolrich; Stephen M Smith Journal: Neuroimage Date: 2011-09-16 Impact factor: 6.556
Authors: Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella Journal: J Cereb Blood Flow Metab Date: 2016-12-22 Impact factor: 6.200
Authors: Tobey J Betthauser; Karly A Cody; Matthew D Zammit; Dhanabalan Murali; Alexander K Converse; Todd E Barnhart; Charles K Stone; Howard A Rowley; Sterling C Johnson; Bradley T Christian Journal: J Nucl Med Date: 2018-05-18 Impact factor: 10.057
Authors: Anne Maass; Samuel N Lockhart; Theresa M Harrison; Rachel K Bell; Taylor Mellinger; Kaitlin Swinnerton; Suzanne L Baker; Gil D Rabinovici; William J Jagust Journal: J Neurosci Date: 2017-11-30 Impact factor: 6.167